Ernexa Therapeutics Inc. (ERNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.86M
Last updated: Nov 17, 2026 at 4:10 PM ET
Ernexa Therapeutics Inc. (ERNA) Statistics
Ernexa Therapeutics (ERNA) has a market cap of $2.86M. It holds $5.58M more cash than debt, 194.90% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $2.86M |
|---|---|
| Latest price (Nov 17, 2026) | $1.63 |
Key Dates
The next earnings report is expected on Mar 11, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 11, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 95.71% over 52 weeks and trades 38.26% below its 50-day average.
| Beta (1Y) | 0.75 |
|---|---|
| 52-Week Change | -95.71% |
| 1-Month Change | -17.68% |
| 3-Month Change | -63.21% |
| 6-Month Change | -85.76% |
| 5-Year Change | -100.00% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -95.71% |
| Total Return (3Y CAGR) | -84.32% |
| Total Return (5Y CAGR) | -87.38% |
| Return vs SPY (1Y) | -107.15% |
| Max Drawdown (1Y) | -95.68% |
| Max Drawdown (3Y) | -99.82% |
| Sharpe Ratio (1Y) | -2.13 |
| Correlation with SPY (1Y) | 0.07 |
| 50-Day Average | $2.64 |
| 200-Day Average | $5.65 |
| 52-Week Range | $1.67 to $37.50 |
| RSI (14 Days) | 30.3 |
| Average Volume (20 Days) | 14.79K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.57x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.57x |
|---|---|
| Quick Ratio | 2.57x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -320.82% and return on assets is -196.49% over the last 12 months.
| Return on Equity (ROE) | -320.82% |
|---|---|
| Return on Assets (ROA) | -196.49% |
Scores
ERNA has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$69.00K |
| Operating Income | -$14.78M |
| Pretax Income | -$14.06M |
| Net Income | -$13.96M |
| EBITDA | -$14.05M |
| Reported EPS (TTM) | -$17.05 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 61.27% of the $7.10M in total assets.
| Cash and Equivalents | $5.58M |
|---|---|
| Total Debt | $0 |
| Net Cash | $5.58M |
| Net Cash Per Share | $3.57 |
| Working Capital | $4.11M |
| Shareholder Equity | $4.35M |
| Book Value Per Share | $2.79 |
| Total Assets | $7.10M |
| Total Liabilities | $2.75M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$10.73M |
|---|---|
| FCF Per Share | -$6.59 |
| Depreciation and Amortization | $245.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
ERNA does not pay a dividend.
| Buyback Yield | -558.48% |
|---|---|
| Shareholder Yield | -558.48% |
Stock Splits
The last split was a 1-for-25 reverse split on May 4, 2026.
| Last Split Date | May 4, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ERNA
What is ERNA's market cap?
Ernexa Therapeutics has a market cap of $2.86M.
How many shares of ERNA are outstanding?
Ernexa Therapeutics has 1.56M shares outstanding.
Does ERNA pay a dividend?
No. Ernexa Therapeutics does not pay a dividend.
How much debt does ERNA have?
Ernexa Therapeutics has $0 of total debt and $5.58M of cash and equivalents, a net cash position of $5.58M.
ERNA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors